PHARMACOKINETICS OF HIGH-DOSE METHYLPREDNISOLONE IN CHILDREN

被引:22
作者
ITO, S
KUSUNOKI, Y
OKA, T
ITO, Y
OKUNO, A
YOSHIOKA, H
机构
[1] HOSP SICK CHILDREN,DEPT PEDIAT,DIV CLIN PHARMACOL & TOXICOL,TORONTO M5G 1X8,ONTARIO,CANADA
[2] ASAHIKAWA MED COLL,DEPT PEDIAT,ASAHIKAWA 07811,JAPAN
来源
DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS | 1992年 / 19卷 / 2-3期
关键词
METHYLPREDNISOLONE; PULSE THERAPY; PHARMACOKINETICS; CHILDREN;
D O I
10.1159/000457470
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Disposition of methylprednisolone was characterized in 11 children receiving the high-dose therapy (26.0 mg/kg on average). After intravenous infusion, methylprednisolone hemisuccinate was rapidly converted to methylprednisolone with a half-life of about 20 min. Methylprednisolone in serum, eliminated monoexponentially in 8 patients and biexponentially in the remaining three, had the mean residence time of about 3 h, and a terminal half-life of 2.5 h. The volume of distribution at steady state, and the clearance were 1.3 liters/kg and 0.5 liters/kg/h, respectively. Although these average pharmacokinetic parameters were comparable to those determined in other studies with conventional low doses, the clearance values in our data were characterized by 5-fold interindividual difference, suggesting large variations in exposures to methylprednisolone among children on the high-dose pulse therapy.
引用
收藏
页码:99 / 105
页数:7
相关论文
共 17 条
[1]   METHYLPREDNISOLONE PHARMACOKINETICS AFTER INTRAVENOUS AND ORAL-ADMINISTRATION [J].
ALHABET, SMH ;
ROGERS, HJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (03) :285-290
[2]   INFLUENCE OF ROUTE OF ADMINISTRATION ON THE PHARMACOKINETICS OF METHYLPREDNISOLONE [J].
ANTAL, EJ ;
WRIGHT, CE ;
GILLESPIE, WR ;
ALBERT, KS .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1983, 11 (06) :561-576
[3]   DISPOSITION OF PULSE DOSE METHYLPREDNISOLONE IN ADULT AND PEDIATRIC-PATIENTS WITH THE NEPHROTIC SYNDROME [J].
ASSAEL, BM ;
BANFI, G ;
APPIANI, AC ;
EDEFONTI, A ;
JUSKO, WJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 23 (05) :429-433
[4]   A RANDOMIZED, CONTROLLED TRIAL OF METHYLPREDNISOLONE OR NALOXONE IN THE TREATMENT OF ACUTE SPINAL-CORD INJURY - RESULTS OF THE 2ND NATIONAL ACUTE SPINAL-CORD INJURY STUDY [J].
BRACKEN, MB ;
SHEPARD, MJ ;
COLLINS, WF ;
HOLFORD, TR ;
YOUNG, W ;
BASKIN, DS ;
EISENBERG, HM ;
FLAMM, E ;
LEOSUMMERS, L ;
MAROON, J ;
MARSHALL, LF ;
PEROT, PL ;
PIEPMEIER, J ;
SONNTAG, VKH ;
WAGNER, FC ;
WILBERGER, JE ;
WINN, HR .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (20) :1405-1411
[5]  
CATHCART ES, 1976, LANCET, V1, P163
[6]   KINETICS OF METHYLPREDNISOLONE AND ITS HEMISUCCINATE ESTER [J].
DERENDORF, H ;
MOLLMANN, H ;
ROHDEWALD, P ;
REHDER, J ;
SCHMIDT, EW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (05) :502-507
[7]  
Gibaldi M., 1982, PHARMACOKINETICS, Vsecond
[8]   MONITORING GLUCOCORTICOID THERAPY - A PHARMACOKINETIC APPROACH [J].
HILL, MR ;
SZEFLER, SJ ;
BALL, BD ;
BARTOSZEK, M ;
BRENNER, AM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (04) :390-398
[9]   INHIBITION OF METHYLPREDNISOLONE ELIMINATION IN THE PRESENCE OF ERYTHROMYCIN THERAPY [J].
LAFORCE, CF ;
SZEFLER, SJ ;
MILLER, MF ;
EBLING, W ;
BRENNER, M .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1983, 72 (01) :34-39
[10]   SYSTEMIC BIOAVAILABILITY AND PHARMACOKINETICS OF METHYLPREDNISOLONE IN PATIENTS WITH RHEUMATOID-ARTHRITIS FOLLOWING HIGH-DOSE PULSE ADMINISTRATION [J].
NARANG, PK ;
WILDER, R ;
CHATTERJI, DC ;
YEAGER, RL ;
GALLELLI, JF .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1983, 4 (03) :233-248